Cite
HARVARD Citation
Monteith, B. et al. (2021). A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. European journal of haematology. pp. 333-342. [Online].